National Lung Matrix Trial: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer

Medicine & Life Sciences

1. Lung Neoplasms 100%
2. Lung 67%
3. Genotype 60%
4. Tobacco 59%
5. Non-Small Cell Lung Carcinoma 56%
6. Smoke 40%
7. Therapeutics 20%
8. High-Throughput Nucleotide Sequencing 20%
9. Medicine 15%
10. Light 14%
11. Neoplasms 13%
12. Pharmaceutical Preparations 8%